MIN-117

MIN-117
Clinical data
Other names	WF-516
Identifiers
	IUPAC name (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol;
CAS Number	310392-94-0;
PubChem CID	9806065;
ChemSpider	7981825;
UNII	QM05G7NM4H;
Chemical and physical data
Formula	C25H25Cl2N3O
Molar mass	454.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O;
	InChI InChI=1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1; Key:XIYDIPLATGRHEC-SFHVURJKSA-N;

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).^[2]^[3]^[4] It is described as a 5-HT_1A and 5-HT_2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,^[4]^[5]^[6] and is also reported to possess affinity for the α_1A- and α_1B-adrenergic receptors.^[4]^[6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.^[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.^[7]